Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7011026 | 0.85 | TSHR (0.74) | TSHRPOLBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL11174344 | 0.83 | SMN1; SMN2 (0.69) | TSHRPOLBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL407668 | 0.82 | CA12 (0.61) | POLBALDH1A1L3MBTL1 | |
| SCHEMBL18229979 | 0.82 | NSD2 (0.54) | POLBKMT2A | |
| SCHEMBL18230002 | 0.79 | KMT2A (0.43) | TSHRPOLBALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL25223925 | 0.78 | KEAP1 (0.68) | POLBALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL18230026 | 0.77 | CYP19A1 (0.69) | ALDH1A1HTTKMT2A | |
| SCHEMBL14623888 | 0.77 | CNR1 (0.58) | ALDH1A1KMT2ANR3C2 | |
| SCHEMBL29717140 | 0.76 | BRD4 (0.49) | TSHRPOLBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL24512257 | 0.76 | BRD4 (0.49) | TSHRPOLBALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | TSHR 4313/4885POLB 387/4885ALDH1A1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.